Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902309 | 0.94 | NISCH (0.55) | MAOBNISCHLMNARECQLTOP2A | |
| SCHEMBL23901782 | 0.91 | NISCH (0.58) | MAOBNISCHTOP2ATOP2B | |
| SCHEMBL15788088 | 0.90 | MAOB (0.74) | MAOBNISCHALDH1A1CYP1A2HPGD | |
| SCHEMBL8195812 | 0.90 | NISCH (0.71) | MAOBNISCHLMNARECQLTOP2A | |
| SCHEMBL23902145 | 0.87 | MAOB (0.48) | MAOBNISCHLMNARECQL | |
| SCHEMBL23902187 | 0.79 | NISCH (0.46) | MAOBNISCHTOP2ATOP2B | |
| SCHEMBL5476725 | 0.78 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL19462115 | 0.78 | MAOB (0.65) | MAOBNISCHLMNARECQLTOP2A | |
| SCHEMBL19877199 | 0.76 | NISCH (0.59) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL21103117 | 0.76 | NISCH (0.58) | MAOBNISCHLMNARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | MAOB 2311/4885NISCH 24/4885LMNA 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.